Neumora Therapeutics (NMRA) Earnings Date, Estimates & Call Transcripts $0.75 +0.02 (+3.41%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.76 +0.00 (+0.19%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Neumora Therapeutics Earnings Summary Neumora Therapeutics released Q1 2025 earnings on May 12, 2025, reporting an EPS of -$0.42, which missed analysts' consensus estimates of -$0.40 by $0.02. With a trailing EPS of -$1.61, Neumora Therapeutics' earnings are expected to grow next year, from ($1.61) to ($1.54) per share. Upcoming Q2 Earnings DateAug. 5After Market ClosesEstimatedConsensus EPS (May. 12) -$0.40 Actual EPS (May. 12) -$0.42 Missed By -$0.02 Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)NMRA Upcoming EarningsNeumora Therapeutics' next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules. Powered by Get Neumora Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neumora Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNMRA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Neumora Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.46-$0.37-$0.42Q2 20252-$0.44-$0.35-$0.40Q3 20252-$0.46-$0.30-$0.38Q4 20252-$0.47-$0.32-$0.40 FY 2025 8 -$1.83 -$1.34 -$1.59 Q1 20262-$0.44-$0.29-$0.37Q2 20262-$0.45-$0.21-$0.33Q3 20262-$0.40-$0.22-$0.31Q4 20262-$0.45-$0.23-$0.34 Neumora Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/5/2025(Estimated)--------5/12/2025Q1 2025-$0.40-$0.42 -$0.02-$0.42--3/6/2025Q4 2024-$0.46-$0.37+$0.09-$0.37--11/12/2024Q3 2024-$0.39-$0.45 -$0.06-$0.45--8/6/2024Q2 2024-$0.37-$0.37--$0.37--5/7/2024Q1 2024-$0.34-$0.34--$0.34--3/7/2024Q4 2023-$0.76-$0.71+$0.05-$0.71--11/1/2023Q3 2023-$0.35-$1.14 -$0.79-$1.14-- Neumora Therapeutics Earnings - Frequently Asked Questions When is Neumora Therapeutics's earnings date? Neumora Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based off last year's report dates. Learn more on NMRA's earnings history. Did Neumora Therapeutics beat their earnings estimates last quarter? In the previous quarter, Neumora Therapeutics (NASDAQ:NMRA) missed the analysts' consensus estimate of ($0.40) by $0.02 with a reported earnings per share (EPS) of ($0.42). Learn more on analysts' earnings estimate vs. NMRA's actual earnings. How can I listen to Neumora Therapeutics's earnings conference call? The conference call for Neumora Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Neumora Therapeutics's conference call transcript? The conference call transcript for Neumora Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Neumora Therapeutics generate each year? Neumora Therapeutics (NASDAQ:NMRA) has a recorded net income of -$235.93 million. NMRA has generated -$1.61 earnings per share over the last four quarters. What is Neumora Therapeutics's EPS forecast for next year? Neumora Therapeutics's earnings are expected to grow from ($1.61) per share to ($1.54) per share in the next year. More Earnings Resources from MarketBeat Related Companies Maze Therapeutics Earnings SIGA Technologies Earnings Zevra Therapeutics Earnings Sage Therapeutics Earnings Amylyx Pharmaceuticals Earnings Prothena Earnings Tourmaline Bio Earnings Precigen Earnings REGENXBIO Earnings Mereo BioPharma Group Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds This page (NASDAQ:NMRA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
